[Comment] New perspectives on semaglutide in cardiovascular disease

The prevalence of overweight and obesity has reached pandemic proportions, affecting more than 1 billion people worldwide; it represents a major driver of cardiovascular morbidity, mortality, and health-care costs.1 Excess adiposity triggers a complex cascade of metabolic and vascular disturbances which increase the risk of atherosclerotic cardiovascular disease, heart failure, and mortality.2,3 GLP-1 receptor agonists have emerged as an important therapy at an intersection of obesity and cardiovascular disease.